UB Paderborn / Katalog / Suche / in CDI

Randomized Controlled Trials in Celiac Disease: Expressing the Patient’s Voice

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.941-942

2024

Volltextzugriff (PDF)

Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus

PloS one, 2008-10, Vol.3 (10), p.e3534-e3534

2008

Volltextzugriff (PDF)

A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

BMC pharmacology & toxicology, 2018-03, Vol.19 (1), p.10-10, Article 10

2018

Volltextzugriff (PDF)

Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice

Gastroenterology (New York, N.Y. 1943), 2002-03, Vol.122 (3), p.689-696

2002

Volltextzugriff (PDF)

Loss of Klf4 in mice causes altered proliferation and differentiation and precancerous changes in the adult stomach

Gastroenterology (New York, N.Y. 1943), 2005-04, Vol.128 (4), p.935-945

2005

Volltextzugriff (PDF)

Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas

The Journal of pathology, 2003-01, Vol.199 (1), p.36-40

2003

Volltextzugriff (PDF)

Development of the pediatric daily ulcerative colitis signs and symptoms scale (DUCS): qualitative research findings

BMC research notes, 2017-09, Vol.10 (1), p.491-491, Article 491

2017

Volltextzugriff (PDF)

Effects of Lesogaberan on Reflux and Lower Esophageal Sphincter Function in Patients With Gastroesophageal Reflux Disease

Gastroenterology (New York, N.Y. 1943), 2010-08, Vol.139 (2), p.409-417

2010

Volltextzugriff (PDF)

Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial

Gut, 2013-09, Vol.62 (9), p.1248-1255

2013

Volltextzugriff (PDF)

A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial

Gut, 2011-09, Vol.60 (9), p.1182-1188

2011

Volltextzugriff (PDF)

Cdx1 and Cdx2 expression during intestinal development

Gastroenterology (New York, N.Y. 1943), 2000-10, Vol.119 (4), p.961-971

2000

Volltextzugriff (PDF)

Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease

Gastroenterology (New York, N.Y. 1943), 2019-12, Vol.157 (6), p.1448-1456.e1

2019

Volltextzugriff (PDF)

Downregulated in adenoma gene encodes a chloride transporter defective in congenital chloride diarrhea

American journal of physiology: Gastrointestinal and liver physiology, 1999-01, Vol.276 (1), p.G185-G192

1999

Volltextzugriff (PDF)

The Homeodomain Transcription Factor Cdx1 Does Not Behave as an Oncogene in Normal Mouse Intestine

Neoplasia (New York, N.Y.), 2008-01, Vol.10 (1), p.8-19

2008

Volltextzugriff (PDF)

PRISM, a Patient-Reported Outcome Instrument, Accurately Measures Symptom Change in Refractory Gastroesophageal Reflux Disease

Digestive diseases and sciences, 2017-03, Vol.62 (3), p.593-606

2017

Volltextzugriff (PDF)

Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study

European journal of drug metabolism and pharmacokinetics, 2018-02, Vol.43 (1), p.91-101

2018

Volltextzugriff (PDF)

Obesity Does Not Affect Treatment Outcomes With Proton Pump Inhibitors

Journal of clinical gastroenterology, 2013-09, Vol.47 (8), p.672-677

2013

Volltextzugriff (PDF)

A Family of Tissue-Specific Resistin-like Molecules

Proceedings of the National Academy of Sciences - PNAS, 2001-01, Vol.98 (2), p.502-506

2001

Volltextzugriff (PDF)

Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study

BMC gastroenterology, 2014-11, Vol.14 (1), p.188-188, Article 188

2014

Volltextzugriff (PDF)

Esophageal mucosal breaks in gastroesophageal reflux disease partially responsive to proton pump inhibitor therapy

The American journal of gastroenterology, 2013-04, Vol.108 (4), p.529-534

2013

Volltextzugriff (PDF)

Intestinal inflammation reduces expression of DRA, a transporter responsible for congenital chloride diarrhea

American journal of physiology: Gastrointestinal and liver physiology, 1998-12, Vol.275 (6), p.G1445-G1453

1998

Volltextzugriff (PDF)

The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice

Cancer research (Chicago, Ill.), 2003-05, Vol.63 (9), p.2005-2009

2003

Volltextzugriff (PDF)

Mo1131 Development and Validation of Prism: A Patient Reported Outcome Measure for GERD Patients Who Are Partial or Non-Responders to PPI Therapy

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-565-S-565

2014

Volltextzugriff (PDF)

Induction of intestinalization in human esophageal keratinocytes is a multistep process

Carcinogenesis (New York), 2009-01, Vol.30 (1), p.122-130

2009

Volltextzugriff (PDF)

Expression of an Intestine-Specific Transcription Factor (CDX1) in Intestinal Metaplasia and in Subsequently Developed Intestinal Type of Cholangiocarcinoma in Rat Liver

The American journal of pathology, 2000-02, Vol.156 (2), p.621-627

2000

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Randomized Controlled Trials in Celiac Disease: Expressing the Patient’s Voice

Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus

A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice

Loss of Klf4 in mice causes altered proliferation and differentiation and precancerous changes in the adult stomach

Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas

Development of the pediatric daily ulcerative colitis signs and symptoms scale (DUCS): qualitative research findings

Effects of Lesogaberan on Reflux and Lower Esophageal Sphincter Function in Patients With Gastroesophageal Reflux Disease

Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial

A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial

Cdx1 and Cdx2 expression during intestinal development

Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease

Downregulated in adenoma gene encodes a chloride transporter defective in congenital chloride diarrhea

The Homeodomain Transcription Factor Cdx1 Does Not Behave as an Oncogene in Normal Mouse Intestine

PRISM, a Patient-Reported Outcome Instrument, Accurately Measures Symptom Change in Refractory Gastroesophageal Reflux Disease

Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study

Obesity Does Not Affect Treatment Outcomes With Proton Pump Inhibitors

A Family of Tissue-Specific Resistin-like Molecules

Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study

Esophageal mucosal breaks in gastroesophageal reflux disease partially responsive to proton pump inhibitor therapy

Intestinal inflammation reduces expression of DRA, a transporter responsible for congenital chloride diarrhea

The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice

Mo1131 Development and Validation of Prism: A Patient Reported Outcome Measure for GERD Patients Who Are Partial or Non-Responders to PPI Therapy

Induction of intestinalization in human esophageal keratinocytes is a multistep process

Expression of an Intestine-Specific Transcription Factor (CDX1) in Intestinal Metaplasia and in Subsequently Developed Intestinal Type of Cholangiocarcinoma in Rat Liver

Suchergebnisse filtern